Journal of Applied Genetics

, Volume 60, Issue 2, pp 175–178 | Cite as

Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1−/− mice

  • Robert P. EricksonEmail author
  • Ivan A. Borbon
Human Genetics • Short Communication


We previously reported the altered pulmonary function and pathology found in the mouse model of infantile Niemann-Pick C1 disease, the Npc1−/− mouse. Despite its salutary properties on brain and liver parameters, we did not find efficacious effects of hydroxypropyl-β-cyclodextrin (HPBCD) on pulmonary pathology. Since we had previously shown the beneficial effects of probucol on the somatic phenotype in the Npc1−/− mice, we have now studied the effects of combined therapy with HPBCD and probucol on the lung with mostly negative results. Body weight and lung weight for body weight were increased in parallel while inspiratory capacity for body weight was markedly decreased. Other physical, biochemical, and pulmonary function parameters were not much changed. There were trends towards improved lung elastance (p = 0.09) and compliance (p = 0.07).


Niemann-pick C1 disease Mouse model Probucol Hydroxypropyl-β-cyclodextrin Pulmonary function Cholesterol storage 



We thank Drs. Gordon A. Francis and Shinji Yokoyama, the University of Alberta, Canada for the gift of probucol and the Abitec Corp., Janesville, WI for the gift of Caprex 300.

Author’s contributions

RPE conceived, helped perform experiments, and wrote the manuscript; IAB performed experiments and analyzed data.


This work was supported by the National Institutes of Health [grant number 5RO1 ED000343-5, Theodore Trouard PI] and the Holsclaw Family Professorship of Human Genetics and Inherited Diseases (RPE).

Compliance with ethical standards

All mouse experiments were approved by our Institutional Review Board.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Camargo F, Erickson RP, Garver WS, Hossain GS, Carbone PN, Heidenreich RA, Blanchard J (2001) Cyclodextrins in the treatments of a mouse model of Niemann-Pick C disease. Life Sci 70:131–142CrossRefGoogle Scholar
  2. Chisolm GM III, Morel DW (1988) Lipoprotein oxidation and cytotoxicity: effect of probucol on streptozotocin-treated rats. Am J Cardiol 62:20B–26BCrossRefGoogle Scholar
  3. Condorelli S, Lombardi D, Gusmano R, Pisano L (1972) Pulmonary A-V differences of lipids and free fatty acids in relation to fasting an to high fat meals. Clin Chim Acta 38:a4a–aa46CrossRefGoogle Scholar
  4. Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU (2009) Chronic cyclodextrin treatment of murine Niemann–Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One 4(9):e6951. CrossRefGoogle Scholar
  5. Deutsch G, Muralidhar A, Le E, Borbon IA, Erickson RP (2016) Extensive macrophage accumulation in young and old Niemann-Pick C1 model mice involves the alternative, M2, activation pathway and inhibition of macrophage apoptosis. Gene 578:242–250CrossRefGoogle Scholar
  6. Erickson RP, Fiorenza MT (August 10, 2017) A hopeful therapy for Niemann-Pick C1 disease. Lancet:1–2Google Scholar
  7. Erickson RP, Garver WS, Camargo F, Hossain GS, Heidenreich RA (2000) Pharmacological and genetic modifications of somatic cholesterol do not substantially alter the course of CNS disease in Niemann-Pick C mice. J Inherit Metab Dis 23:54–62CrossRefGoogle Scholar
  8. Franceschini G, Werba JP, Calabreesi L (1994) Drug control of reverse cholesterol transport. Pharmac Ther 61:289–324CrossRefGoogle Scholar
  9. Fu R, Yanjanin NM, Bianconi S, Pavan WJ, Porter FD (2010) Oxidative stress in Niemann–Pick disease, type C. Mol Genet Metab 101:214–218CrossRefGoogle Scholar
  10. Goldberg RB, Mendez A (1988) Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Amer J Cardiol 62:57B–59BCrossRefGoogle Scholar
  11. Guillemot N, Troadec C, Billete de Villemeur T, Clement A, Fauroux B (2007) Lung disease in Niemann-Pick disease. Pediatr Pulmonol 42:1207–1214CrossRefGoogle Scholar
  12. Hong S-c, Zhao S-p, Wu Z-h (2006) Provuco upregulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits. J Cardiovasc Pharmacol 47:77–81CrossRefGoogle Scholar
  13. Liu B, Xie C, Richardson JA, Turley SD, Dietschy JM (2007) Receptor-mediated and bulk-phase endocytosis cause macrophage and cholesterol accumulation in Niemann-Pick C disease. J Lipid Res 48:1710–1723CrossRefGoogle Scholar
  14. Liu B, Turley SD, Burns DK, Miller AM, Repa JJ, Dietschy JM (2009) Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. Proc Natl Acad Sci U S A 106:2377–2382CrossRefGoogle Scholar
  15. Muralidhar A, Borbon IA, Esharif DM, Ke W, Manacheril R, Daines M, Erickson RP (2011) Pulmonary function and pathology in hyeroxypropyl-beta-cyclodextrin-treated and untreated Npc1−/− mice. Molec Genet Metab 103:142–147CrossRefGoogle Scholar
  16. Ory DS, Ottinger EA, Farhat NY et al (2017) Intrathecal 2-hydroxypropyl-beta-cyclodextrin decreases neurological disease progression in Niemann-Pick Disease, type C1: an ad-hoc analysis of a non-randomized, open-label, phase 1–2 trial. Lancet.
  17. Ramirez CM, Liu B, Taylor AM, Repa JJ, Burns DK (2010) Weekly cyclodextrin administration normalizes cholesterol metabolism in nearly every organ of the Niemann-Pick type C1 mouse and markedly prolongs life. Ped Res 68:309–315CrossRefGoogle Scholar
  18. Scholfer O, Mischo B, Puschel W, Harzer K, Vanier MT (1998) Early-lethal pulmonary Niemann-Pick type C disease belonging to a second, rare genetic complementation group. Eur J Pediatr 157:45–49CrossRefGoogle Scholar
  19. Vazquez MC, del Pozo T, Robledo FA, Carrasco G, Pavez L, Olivares F, Gonzalez M, Zanlungo S (2011) Alteration of gene expression profile in Niemann–Pick Type C mice correlates with tissue damage and oxidative stress. PLoS One, 6 (12) (2011), e28777,
  20. Weigert A, Johann AM, von Knethen A, Schmidt H, Geisslinger G, Brune B (2006) Apoptotic cells promote macrophage survival by releasing the anti-apoptotic mediator sphingosine-1-phosphate. Blood 108:1635–1642Google Scholar
  21. Yamamoto A, Takaichi S, Hara H, Nishikawa O, Yokoyama S, Yamamura T, Yamaguchi T (1986) Probucol prevents lipid storage in macrophages. Atherosclerosis 62:209–217CrossRefGoogle Scholar
  22. Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tal AR (2010) lABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res 106:1861–1869CrossRefGoogle Scholar

Copyright information

© Institute of Plant Genetics, Polish Academy of Sciences, Poznan 2019

Authors and Affiliations

  1. 1.Department of pediatricsUniversity of Arizona College of medicineTucsonUSA

Personalised recommendations